
Razelle Kurzrock: Once Again, DART Hits A Target
Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, posted on X:
“Once again, DART hits a target.”
Title: SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
Journal: Clinical Cancer Research, AACR
Authors: Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves, Jayanthi Lea, John M Schallenkamp, Nabil Adra, Leonard J Appleman, Mitchell Alden, Jessica Thomes Pepin, John A Ellerton, Andrew Poklepovic, Adam Walter, Murtuza M Rampurwala, William R Robinson, Hye Sung Kim, Liam Il-Young Chung, Christine M McLeod, Gabby Lopez, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles D Blanke, Razelle Kurzrock
Also read OncoDaily’s special article “Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine“.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023